David Planchard, Thoracic Pathologist Committee at Gustave Roussy, shared a post on X:
“Two superb post osimertinib studies (Savannah and Orchad) in EGFRmut NSCLC, promising post osimertinib 1L (preferred option) strategies…an important need for our patients!”
